Duloxetine: a new selective and dual-acting antidepressant

Expert Opinion on Pharmacotherapy
M BauerE Schneider

Abstract

Antidepressants that inhibit the re-uptake of serotonin and noradrenaline might offer a chance to reduce the multiple symptoms of depression, as both serotonin and noradrenaline seem to be responsible for the emotional and physical symptoms of depression. The potential superiority of a dual mechanism of action has already been demonstrated in a number of clinical trials. Duloxetine, a novel dual acting, selective serotonin and noradrenaline-re-uptake inhibitor, has demonstrated high remission rates and good efficacy on physical symptoms, especially painful physical symptoms of depression. The results from studies in diabetic neuropathic pain provide further evidence of the effect of duloxetine on pain, independent of its effect on depression. Therefore, duloxetine provides an alternative to current therapeutic options in the treatment of the different symptoms of depression.

References

Mar 1, 1972·American Journal of Surgery·M Wernicke
Jan 1, 1994·International Clinical Psychopharmacology·S A MontgomeryD Nutt
Apr 16, 1998·European Journal of Pharmacology·M TatsumiE Richelson
Feb 9, 2000·Journal of Clinical Pharmacology·A SharmaB J Cerimele
Jun 1, 2000·The Journal of Clinical Psychiatry·R M HirschfeldM Bourgeois
Dec 26, 2001·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·F P BymasterD T Wong
Apr 3, 2002·The Journal of Clinical Psychiatry·David J GoldsteinMark A Demitrack
May 10, 2002·The Journal of Clinical Psychiatry·Michael J DetkeMark A Demitrack
May 22, 2002·The Journal of Clinical Psychiatry·Stephen M Stahl
Oct 24, 2002·Journal of Psychiatric Research·Michael J DetkeMark A Demitrack
Dec 14, 2002·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·Michael BauerUNKNOWN World Federation of Societies Biological Psychiatry Task Force on Treatment Guidelines for Unipolar Depressive Disorders
Mar 7, 2003·Clinical Pharmacology and Therapeutics·Michael H SkinnerStephen D Wise
Aug 16, 2003·Drug Metabolism and Disposition : the Biological Fate of Chemicals·R J LantzM P Knadler
Sep 10, 2003·Depression and Anxiety·David L DunnerMichael J Detke
Dec 9, 2003·The Journal of Clinical Psychiatry·Joel RaskinMargaret B Ferguson
Dec 18, 2003·British Journal of Clinical Pharmacology·Michael H SkinnerMary P Knadler
Jan 8, 2004·Psychosomatics·David J GoldsteinMark A Demitrack
May 25, 2004·Primary Care Companion to the Journal of Clinical Psychiatry·Craig H. MallinckrodtPierre V. Tran
Jun 16, 2004·European Psychiatry : the Journal of the Association of European Psychiatrists·Lefteris LykourasAlexander Botsis
Jun 24, 2004·Primary Care Companion to the Journal of Clinical Psychiatry·Madelaine M. Wohlreich, John G. Watkin
Jul 3, 2004·Journal of Clinical Psychopharmacology·David J GoldsteinMark A Demitrack
Jul 10, 2004·Journal of General Internal Medicine·Teri GrecoKurt Kroenke
Jul 16, 2004·The Journal of Pharmacology and Experimental Therapeutics·Smriti IyengarRosa Maria A Simmons
Sep 25, 2004·The Journal of the American Dental Association·Jack J Hirschfeld
Dec 14, 2004·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Michael J DetkeIstvan Bitter
Mar 2, 2005·Journal of Clinical Psychopharmacology·Michael E ThaseMichael J Detke
Jun 2, 2005·Pain·David J GoldsteinSmriti Iyengar

❮ Previous
Next ❯

Citations

Feb 17, 2010·The Consultant Pharmacist : the Journal of the American Society of Consultant Pharmacists·Michael NamakaHoward Intrater
Jul 16, 2008·Bioorganic & Medicinal Chemistry Letters·Florian WakenhutGavin A Whitlock
Apr 18, 2008·Bioorganic & Medicinal Chemistry Letters·Gavin A WhitlockFlorian Wakenhut
Apr 18, 2008·Expert Review of Neurotherapeutics·Norbert MüllerHans-Jürgen Möller
Feb 19, 2008·Journal of Affective Disorders·Anthony L VaccarinoAmir H Kalali
Oct 22, 2016·Critical Reviews in Analytical Chemistry·M Kątny, M Frankowski
Dec 17, 2008·Psychosomatic Medicine·Anthony L VaccarinoAmir H Kalali
Dec 9, 2009·Harvard Review of Psychiatry·Stephen E NicolsonTheodore A Stern

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Clinical Medicine : Journal of the Royal College of Physicians of London
Cornelius KatonaElizabeth Wager
Journal of Psychosomatic Research
Roger S McIntyreSidney H Kennedy
International Journal of Psychiatry in Medicine
Russell NoyesStephen J Yagla
© 2021 Meta ULC. All rights reserved